Drug design strategies: quantitative approaches
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Cambridge
Royal Society of Chemistry ; [LaVergne] [Ingram Publisher Services]
2012
|
| Schriftenreihe: | RSC drug discovery series
13 |
| Schlagworte: | |
| Beschreibung: | 1 online resource (516 pages) illustrations |
| ISBN: | 9781621981404 1621981401 9781849733410 1849733414 9781849731676 1849731675 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV045344913 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 181206s2012 |||| o||u| ||||||eng d | ||
| 020 | |a 9781621981404 |9 978-1-62198-140-4 | ||
| 020 | |a 1621981401 |9 1-62198-140-1 | ||
| 020 | |a 9781849733410 |9 978-1-84973-341-0 | ||
| 020 | |a 1849733414 |9 1-84973-341-4 | ||
| 020 | |a 9781849731676 |9 978-1-84973-167-6 | ||
| 020 | |a 1849731675 |9 1-84973-167-5 | ||
| 035 | |a (ZDB-4-ENC)ocn798795445 | ||
| 035 | |a (OCoLC)798795445 | ||
| 035 | |a (DE-599)BVBBV045344913 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 615.19 |2 23 | |
| 084 | |a VC 6250 |0 (DE-625)147086:253 |2 rvk | ||
| 245 | 1 | 0 | |a Drug design strategies |b quantitative approaches |c edited by David J. Livingstone, Andrew M. Davis |
| 264 | 1 | |a Cambridge |b Royal Society of Chemistry ; [LaVergne] |b [Ingram Publisher Services] |c 2012 | |
| 300 | |a 1 online resource (516 pages) |b illustrations | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a RSC drug discovery series |v 13 | |
| 505 | 8 | |a This book brings together drug design practitioners, all leaders in their field, who are actively advancing the field of quantitative methods to guide drug discovery, from structure-based design to empirical statistical models - from rule-based approaches to toxicology to the fields of bioinformatics and systems biology. The aim of the book is to show how various facets of the drug discovery process can be addressed in a quantitative fashion (ie: numerical analysis to enable robust predictions to be made). Each chapter includes a brief review of the topic showing the historical development of quantitative approaches, a survey/summary of the current state-of-the-art, a selection of well chosen examples with some worked through and an appreciation of what problems remain to be overcome as well as an indication of how the field may develop. | |
| 505 | 8 | |a After an overview of quantitative approaches to drug design the book describes the development of concepts of "drug-like properties", of quantitative structure-activity relationships and molecular modelling, and in particular, structure-based design approaches to guide lead optimisation. How to manage and describe chemical structures, underpins all quantitative approaches to drug design and these are described in the following chapters. The next chapter covers the value of a quantitative approach, and also the challenge which is to describe the confidence in any prediction, and methods to assess predictive model quality. The later chapters describe the application of quantitative approaches to describing and optimising potency, selectivity, drug metabolism and pharmacokinetic properties and toxicology, and the design of chemical libraries to feed the screening approaches to lead generation that underpin modern drug discovery. | |
| 505 | 8 | |a Finally the book describes the impact of bioinformatics, current status of predicting ligand affinity direct from the protein structure, and the application of quantitative approaches to predicting environmental risk. The book provides a summary of the current state-of-the-art in quantitative approaches to drug design, and future opportunities, but it also provides inspiration to drug design practitioners to apply careful design, to make best use of the quantitative methods that are available, while continuing to improve them. Drug discovery still relies heavily on random screening and empirical screening cascades to identify leads and drugs and the process has many failures to deliver only a small handful of drugs. With the rapidly escalating costs of drug discovery and development together with spiralling delivery, quantitative approaches hold the promise of shifting the balance of success, to enable drug discovery to maintain its economic viability | |
| 650 | 7 | |a MEDICAL / Drug Guides |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Nursing / Pharmacology |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacy |2 bisacsh | |
| 650 | 7 | |a Drugs / Design |2 fast | |
| 650 | 4 | |a Drug Design | |
| 650 | 4 | |a Drug Discovery | |
| 650 | 4 | |a Decision Support Techniques | |
| 650 | 4 | |a Models, Chemical | |
| 650 | 4 | |a Models, Molecular | |
| 650 | 4 | |a Quantitative Structure-Activity Relationship | |
| 650 | 4 | |a Computer Simulation | |
| 650 | 4 | |a Drugs |x Design | |
| 700 | 1 | |a Livingstone, D. |e Sonstige |4 oth | |
| 700 | 1 | |a Davis, Andrew M. |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |t Drug design strategies |d Cambridge : Royal Society of Chemistry, 2012 |z 9781849731676 |
| 912 | |a ZDB-4-ENC | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-030731616 | ||
Datensatz im Suchindex
| _version_ | 1804179165119774720 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV045344913 |
| classification_rvk | VC 6250 |
| collection | ZDB-4-ENC |
| contents | This book brings together drug design practitioners, all leaders in their field, who are actively advancing the field of quantitative methods to guide drug discovery, from structure-based design to empirical statistical models - from rule-based approaches to toxicology to the fields of bioinformatics and systems biology. The aim of the book is to show how various facets of the drug discovery process can be addressed in a quantitative fashion (ie: numerical analysis to enable robust predictions to be made). Each chapter includes a brief review of the topic showing the historical development of quantitative approaches, a survey/summary of the current state-of-the-art, a selection of well chosen examples with some worked through and an appreciation of what problems remain to be overcome as well as an indication of how the field may develop. After an overview of quantitative approaches to drug design the book describes the development of concepts of "drug-like properties", of quantitative structure-activity relationships and molecular modelling, and in particular, structure-based design approaches to guide lead optimisation. How to manage and describe chemical structures, underpins all quantitative approaches to drug design and these are described in the following chapters. The next chapter covers the value of a quantitative approach, and also the challenge which is to describe the confidence in any prediction, and methods to assess predictive model quality. The later chapters describe the application of quantitative approaches to describing and optimising potency, selectivity, drug metabolism and pharmacokinetic properties and toxicology, and the design of chemical libraries to feed the screening approaches to lead generation that underpin modern drug discovery. Finally the book describes the impact of bioinformatics, current status of predicting ligand affinity direct from the protein structure, and the application of quantitative approaches to predicting environmental risk. The book provides a summary of the current state-of-the-art in quantitative approaches to drug design, and future opportunities, but it also provides inspiration to drug design practitioners to apply careful design, to make best use of the quantitative methods that are available, while continuing to improve them. Drug discovery still relies heavily on random screening and empirical screening cascades to identify leads and drugs and the process has many failures to deliver only a small handful of drugs. With the rapidly escalating costs of drug discovery and development together with spiralling delivery, quantitative approaches hold the promise of shifting the balance of success, to enable drug discovery to maintain its economic viability |
| ctrlnum | (ZDB-4-ENC)ocn798795445 (OCoLC)798795445 (DE-599)BVBBV045344913 |
| dewey-full | 615.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.19 |
| dewey-search | 615.19 |
| dewey-sort | 3615.19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04751nmm a2200577zcb4500</leader><controlfield tag="001">BV045344913</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">181206s2012 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781621981404</subfield><subfield code="9">978-1-62198-140-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1621981401</subfield><subfield code="9">1-62198-140-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781849733410</subfield><subfield code="9">978-1-84973-341-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1849733414</subfield><subfield code="9">1-84973-341-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781849731676</subfield><subfield code="9">978-1-84973-167-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1849731675</subfield><subfield code="9">1-84973-167-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-ENC)ocn798795445</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)798795445</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV045344913</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.19</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VC 6250</subfield><subfield code="0">(DE-625)147086:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug design strategies</subfield><subfield code="b">quantitative approaches</subfield><subfield code="c">edited by David J. Livingstone, Andrew M. Davis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge</subfield><subfield code="b">Royal Society of Chemistry ; [LaVergne]</subfield><subfield code="b">[Ingram Publisher Services]</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (516 pages)</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">RSC drug discovery series</subfield><subfield code="v">13</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">This book brings together drug design practitioners, all leaders in their field, who are actively advancing the field of quantitative methods to guide drug discovery, from structure-based design to empirical statistical models - from rule-based approaches to toxicology to the fields of bioinformatics and systems biology. The aim of the book is to show how various facets of the drug discovery process can be addressed in a quantitative fashion (ie: numerical analysis to enable robust predictions to be made). Each chapter includes a brief review of the topic showing the historical development of quantitative approaches, a survey/summary of the current state-of-the-art, a selection of well chosen examples with some worked through and an appreciation of what problems remain to be overcome as well as an indication of how the field may develop. </subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">After an overview of quantitative approaches to drug design the book describes the development of concepts of "drug-like properties", of quantitative structure-activity relationships and molecular modelling, and in particular, structure-based design approaches to guide lead optimisation. How to manage and describe chemical structures, underpins all quantitative approaches to drug design and these are described in the following chapters. The next chapter covers the value of a quantitative approach, and also the challenge which is to describe the confidence in any prediction, and methods to assess predictive model quality. The later chapters describe the application of quantitative approaches to describing and optimising potency, selectivity, drug metabolism and pharmacokinetic properties and toxicology, and the design of chemical libraries to feed the screening approaches to lead generation that underpin modern drug discovery. </subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Finally the book describes the impact of bioinformatics, current status of predicting ligand affinity direct from the protein structure, and the application of quantitative approaches to predicting environmental risk. The book provides a summary of the current state-of-the-art in quantitative approaches to drug design, and future opportunities, but it also provides inspiration to drug design practitioners to apply careful design, to make best use of the quantitative methods that are available, while continuing to improve them. Drug discovery still relies heavily on random screening and empirical screening cascades to identify leads and drugs and the process has many failures to deliver only a small handful of drugs. With the rapidly escalating costs of drug discovery and development together with spiralling delivery, quantitative approaches hold the promise of shifting the balance of success, to enable drug discovery to maintain its economic viability</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Drug Guides</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Nursing / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacy</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs / Design</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Discovery</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Decision Support Techniques</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Models, Chemical</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Models, Molecular</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Quantitative Structure-Activity Relationship</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Computer Simulation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Design</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Livingstone, D.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Davis, Andrew M.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="t">Drug design strategies</subfield><subfield code="d">Cambridge : Royal Society of Chemistry, 2012</subfield><subfield code="z">9781849731676</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-ENC</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030731616</subfield></datafield></record></collection> |
| id | DE-604.BV045344913 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T08:15:31Z |
| institution | BVB |
| isbn | 9781621981404 1621981401 9781849733410 1849733414 9781849731676 1849731675 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030731616 |
| oclc_num | 798795445 |
| open_access_boolean | |
| physical | 1 online resource (516 pages) illustrations |
| psigel | ZDB-4-ENC |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | Royal Society of Chemistry ; [LaVergne] [Ingram Publisher Services] |
| record_format | marc |
| series2 | RSC drug discovery series |
| spelling | Drug design strategies quantitative approaches edited by David J. Livingstone, Andrew M. Davis Cambridge Royal Society of Chemistry ; [LaVergne] [Ingram Publisher Services] 2012 1 online resource (516 pages) illustrations txt rdacontent c rdamedia cr rdacarrier RSC drug discovery series 13 This book brings together drug design practitioners, all leaders in their field, who are actively advancing the field of quantitative methods to guide drug discovery, from structure-based design to empirical statistical models - from rule-based approaches to toxicology to the fields of bioinformatics and systems biology. The aim of the book is to show how various facets of the drug discovery process can be addressed in a quantitative fashion (ie: numerical analysis to enable robust predictions to be made). Each chapter includes a brief review of the topic showing the historical development of quantitative approaches, a survey/summary of the current state-of-the-art, a selection of well chosen examples with some worked through and an appreciation of what problems remain to be overcome as well as an indication of how the field may develop. After an overview of quantitative approaches to drug design the book describes the development of concepts of "drug-like properties", of quantitative structure-activity relationships and molecular modelling, and in particular, structure-based design approaches to guide lead optimisation. How to manage and describe chemical structures, underpins all quantitative approaches to drug design and these are described in the following chapters. The next chapter covers the value of a quantitative approach, and also the challenge which is to describe the confidence in any prediction, and methods to assess predictive model quality. The later chapters describe the application of quantitative approaches to describing and optimising potency, selectivity, drug metabolism and pharmacokinetic properties and toxicology, and the design of chemical libraries to feed the screening approaches to lead generation that underpin modern drug discovery. Finally the book describes the impact of bioinformatics, current status of predicting ligand affinity direct from the protein structure, and the application of quantitative approaches to predicting environmental risk. The book provides a summary of the current state-of-the-art in quantitative approaches to drug design, and future opportunities, but it also provides inspiration to drug design practitioners to apply careful design, to make best use of the quantitative methods that are available, while continuing to improve them. Drug discovery still relies heavily on random screening and empirical screening cascades to identify leads and drugs and the process has many failures to deliver only a small handful of drugs. With the rapidly escalating costs of drug discovery and development together with spiralling delivery, quantitative approaches hold the promise of shifting the balance of success, to enable drug discovery to maintain its economic viability MEDICAL / Drug Guides bisacsh MEDICAL / Nursing / Pharmacology bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh Drugs / Design fast Drug Design Drug Discovery Decision Support Techniques Models, Chemical Models, Molecular Quantitative Structure-Activity Relationship Computer Simulation Drugs Design Livingstone, D. Sonstige oth Davis, Andrew M. Sonstige oth Erscheint auch als Druck-Ausgabe Drug design strategies Cambridge : Royal Society of Chemistry, 2012 9781849731676 |
| spellingShingle | Drug design strategies quantitative approaches This book brings together drug design practitioners, all leaders in their field, who are actively advancing the field of quantitative methods to guide drug discovery, from structure-based design to empirical statistical models - from rule-based approaches to toxicology to the fields of bioinformatics and systems biology. The aim of the book is to show how various facets of the drug discovery process can be addressed in a quantitative fashion (ie: numerical analysis to enable robust predictions to be made). Each chapter includes a brief review of the topic showing the historical development of quantitative approaches, a survey/summary of the current state-of-the-art, a selection of well chosen examples with some worked through and an appreciation of what problems remain to be overcome as well as an indication of how the field may develop. After an overview of quantitative approaches to drug design the book describes the development of concepts of "drug-like properties", of quantitative structure-activity relationships and molecular modelling, and in particular, structure-based design approaches to guide lead optimisation. How to manage and describe chemical structures, underpins all quantitative approaches to drug design and these are described in the following chapters. The next chapter covers the value of a quantitative approach, and also the challenge which is to describe the confidence in any prediction, and methods to assess predictive model quality. The later chapters describe the application of quantitative approaches to describing and optimising potency, selectivity, drug metabolism and pharmacokinetic properties and toxicology, and the design of chemical libraries to feed the screening approaches to lead generation that underpin modern drug discovery. Finally the book describes the impact of bioinformatics, current status of predicting ligand affinity direct from the protein structure, and the application of quantitative approaches to predicting environmental risk. The book provides a summary of the current state-of-the-art in quantitative approaches to drug design, and future opportunities, but it also provides inspiration to drug design practitioners to apply careful design, to make best use of the quantitative methods that are available, while continuing to improve them. Drug discovery still relies heavily on random screening and empirical screening cascades to identify leads and drugs and the process has many failures to deliver only a small handful of drugs. With the rapidly escalating costs of drug discovery and development together with spiralling delivery, quantitative approaches hold the promise of shifting the balance of success, to enable drug discovery to maintain its economic viability MEDICAL / Drug Guides bisacsh MEDICAL / Nursing / Pharmacology bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh Drugs / Design fast Drug Design Drug Discovery Decision Support Techniques Models, Chemical Models, Molecular Quantitative Structure-Activity Relationship Computer Simulation Drugs Design |
| title | Drug design strategies quantitative approaches |
| title_auth | Drug design strategies quantitative approaches |
| title_exact_search | Drug design strategies quantitative approaches |
| title_full | Drug design strategies quantitative approaches edited by David J. Livingstone, Andrew M. Davis |
| title_fullStr | Drug design strategies quantitative approaches edited by David J. Livingstone, Andrew M. Davis |
| title_full_unstemmed | Drug design strategies quantitative approaches edited by David J. Livingstone, Andrew M. Davis |
| title_short | Drug design strategies |
| title_sort | drug design strategies quantitative approaches |
| title_sub | quantitative approaches |
| topic | MEDICAL / Drug Guides bisacsh MEDICAL / Nursing / Pharmacology bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh Drugs / Design fast Drug Design Drug Discovery Decision Support Techniques Models, Chemical Models, Molecular Quantitative Structure-Activity Relationship Computer Simulation Drugs Design |
| topic_facet | MEDICAL / Drug Guides MEDICAL / Nursing / Pharmacology MEDICAL / Pharmacology MEDICAL / Pharmacy Drugs / Design Drug Design Drug Discovery Decision Support Techniques Models, Chemical Models, Molecular Quantitative Structure-Activity Relationship Computer Simulation Drugs Design |
| work_keys_str_mv | AT livingstoned drugdesignstrategiesquantitativeapproaches AT davisandrewm drugdesignstrategiesquantitativeapproaches |